NPC 32
Alternative Names: NPC-32Latest Information Update: 07 Nov 2025
At a glance
- Originator Nobelpharma
- Developer National Defense Medical College; Nobelpharma
- Class Antihaemorrhagics
- Mechanism of Action Platelet aggregation stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Blood coagulation disorders